Advertisement

The Treatment of Metastatic Breast Cancer with 5-Fluorouracil and Leucovorin

  • C. J. Allegra
  • G. F. Egan
  • J. C. Drake
  • S. M. Steinberg
  • S. M. Swain
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 131)

Abstract

The preclinical rationale for the use of 5-fluorouracil (5-FU) in combination with leucovorin has been well described in a number of articles [1]. Briefly, the formation and stability of the ternary complex formed between an active metabolite of 5-FU (FdUMP), thymidylate synthase (TS), and the reduced folate 5-10-methylene tetrahydrofolate is highly dependent on the concentration and polyglutamated state of the folate [2,3]. The addition of exogenous folate has been shown to enhance ternary complex formation, and thereby enzyme inhibition, in in vitro and in vivo investigations [4,5]. Inhibition of TS results in thymidylate deficiency and presumably cytotoxicity due to a diminished ability of cells to replicate and repair DNA. In light of the encouraging experience using 5-FU with leucovorin for the treatment of metastatic colon cancer [1], we sought to test this combination for the therapy of metastatic breast cancer wherein 5-FU is known to be an active agent. The objectives of our study were twofold: 1) to assess the efficacy of 5-FU combined with leucovorin for the treatment of metastatic breast cancer, and 2) to determine the effect of leucovorin on the binding of FdUMP to TS in serial tumor samples obtained from patients undergoing therapy. This report represents a preliminary assessment of the efficacy and toxicity of the 5-FU and leucovorin combination and the biochemical studies relevant to the interaction of 5-FU with TS.

Keywords

Metastatic Breast Cancer Biochemical Evaluation Metastatic Colon Cancer Leucovorin Calcium Preclinical Rationale 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J.L. Grem, D.F. Hoth, J.M. Hamilton, S.A. King and B. Leyland-Jones, Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid, Cancer Treat. Rep. 71: 1249–1264 (1987).Google Scholar
  2. 2.
    C.J. Allegra, B.A. Chabner, J.C. Drake, R. Lutz, D. Rodbard and J. Jolivet, Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates, J. Biol. Chem. 260: 9720–9726 (1985).PubMedGoogle Scholar
  3. 3.
    A. Lockshin and P.V. Dannenberg, Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthase, Biochem. Pharmacol. 30: 247–257 (1981).Google Scholar
  4. 4.
    J.A. Houghton, S.J. Maroda, J.O. Phillips and P.J. Houghton, Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice, Cancer Res. 41: 144–149 (1981).PubMedGoogle Scholar
  5. 5.
    D. Santi, A biochemical rationale for the use of 5-fluorouracil in combination with leucovorin, in: “The Current Status of 5-FluorouracilLeucovorin Calcium Combinations,” H.W. Bruckner and Y.M. Rustum, eds., Park Row Publishers, New York (1984).Google Scholar
  6. 6.
    R.G. Moran, C.P. Spears and C. Heidelberger, Biochemical determinants of tumor sensitivity to 5-FU: ultrasensitive methods for the determination of 5-fluoro-2’-deoxyuridylate, 2’-deoxyuridylate, and thymidylate synthase. Proc. Natl. Acad. Sci. USA 76: 1456–1460 (1979).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • C. J. Allegra
    • 1
  • G. F. Egan
    • 1
  • J. C. Drake
    • 1
  • S. M. Steinberg
    • 1
  • S. M. Swain
    • 1
  1. 1.Clinical Pharmacology Branch Division of Cancer TreatmentNational Cancer InstituteBethesdaUSA

Personalised recommendations